Safety, tolerability and immunogenicity of SPVX02, a room temperature-stabilised Tetanus-Diphtheria vaccine compared to Tetadif and diTeBooster: a multicentre, phase 1, blinded, randomised clinical trial.

This multicentre, phase 1, blinded, randomised clinical trial demonstrates that SPVX02, a novel room-temperature-stable tetanus-diphtheria vaccine, is safe, well-tolerated, and induces immunogenicity comparable to existing approved vaccines, offering a promising solution to overcome cold chain limitations in global vaccine distribution.

The Gist

The Big Problem: The "Perishable Ice Cream" Dilemma

Imagine vaccines are like premium ice cream. They are delicious and life-saving, but they melt instantly if they get too warm. To keep them safe, they must be shipped in giant, expensive refrigerated trucks and stored in fridges. This is called the "cold chain."

The problem is that in many parts of the world, there are no fridges, or the power goes out often. If the ice cream melts, it's ruined. If it freezes too hard, it also gets ruined. This means millions of doses of life-saving medicine are thrown away every year, and people in remote areas can't get the protection they need.

The Solution: A "Dehydrated Backpack"

Enter a new vaccine called SPVX02. Think of this vaccine not as ice cream, but as freeze-dried backpacking food (like the kind astronauts or hikers eat).

• The Old Way: You have to keep the food in a cooler.
• The New Way: The food is dehydrated (lyophilized). It's a dry powder that can sit in a hot backpack for months without spoiling. When you are ready to eat, you just add a little water, and poof—it's ready to go.

This new vaccine is a "room temperature" version of a Tetanus and Diphtheria shot. It was designed to survive heat (up to 30°C/86°F) and even survive being frozen, which usually kills other vaccines.

The Experiment: The "Taste Test"

The researchers wanted to see if this new "backpack food" was safe and if it worked just as well as the "fridge food" (the standard vaccines people get today).

• The Setup: They gathered 60 healthy adults (ages 18–55) who hadn't had a booster shot in over 10 years.
• The Groups: They split the people into three teams:
  1. Team SPVX02: Got the new room-temperature powder mixed with water.
  2. Team Tetadif: Got the standard, fridge-required vaccine (the "gold standard").
  3. Team diTeBooster: Got a different, well-known fridge vaccine.
• The Blindfold: Neither the patients nor the doctors knew who got which shot. This ensures the results are fair.

The Results: A Perfect Score

After 28 days, the researchers checked the results. Here is what they found:

1. Safety (The "Stomach Check"):

   • Did anyone get sick? A few people had mild sore arms or a slight headache (like a mild hangover), but no one had a serious reaction.
   • There were no severe side effects. The new vaccine was just as gentle on the body as the old ones.

2. Effectiveness (The "Shield Check"):

   • The researchers looked at the participants' blood to see if their immune systems built a "shield" against Tetanus and Diphtheria.
   • The Verdict: The new vaccine built a shield just as strong as the standard vaccines. In fact, 100% of the people who got the new shot had high levels of protection against Tetanus, and almost everyone had protection against Diphtheria.

Why This Matters: The "Game Changer"

This study is a "first-in-human" success. It proves that you can take a vaccine that usually needs a fridge and turn it into a shelf-stable powder without losing its power.

Imagine the impact:

• No More Melting: You can send these vaccines in a regular truck, not a refrigerated one.
• No More Waste: If a power outage happens, the vaccine doesn't melt. It stays safe.
• Faster Response: If an outbreak happens in a remote village, you can drop the vaccines off and use them immediately without waiting for a generator to cool them down.

The Bottom Line

The scientists have successfully turned a "perishable ice cream" into "shelf-stable backpack food." The new vaccine (SPVX02) is safe, works perfectly, and doesn't need a fridge. While they need to do a bigger study to get official approval, this small trial is a massive step toward making vaccines accessible to everyone, everywhere, regardless of whether they have electricity or a fridge.

Technical Summary

1. Problem Statement

• Cold Chain Dependency: Global vaccine deployment is severely constrained by the requirement for strict cold chain storage (2°C–8°C for most vaccines; -60°C to -80°C for some nucleic acid vaccines).
• Logistical and Environmental Burden: Maintaining the cold chain is costly, energy-intensive, and generates significant greenhouse gas emissions. It is particularly challenging in resource-limited settings with fragile infrastructure.
• Vaccine Wastage: A significant number of vaccine doses are spoiled due to exposure to heat or freezing during storage and transport.
• Specific Gap: While lyophilization (freeze-drying) is used to improve stability, most marketed lyophilised vaccines still require refrigeration and separate diluents. There is a critical need for fridge-free, room-temperature-stable formulations of essential vaccines like Tetanus-Diphtheria (Td) that do not lose potency when frozen or heated.

2. Methodology

• Study Design: A multicentre, Phase 1, first-in-human, blinded, randomised, active-controlled clinical trial.
• Intervention:
  • SPVX02: A novel, lyophilised, fridge-free reformulation of the Tetanus-Diphtheria vaccine (based on Tetadif) using StablevaX technology. It is stable at temperatures up to 30°C for at least 18 months and is not degraded by freezing. It requires reconstitution with sterile water.
  • Comparators: Two approved Td vaccines: Tetadif (liquid, cold-chain dependent) and diTeBooster (liquid, cold-chain dependent).
• Participants: 60 healthy adults (aged 18–55, BMI ≤32 kg/m²) who had received a Td vaccination >10 years prior.
• Randomisation: Participants were assigned 1:1:1 to receive SPVX02, Tetadif, or diTeBooster. A sentinel group (3 participants) was dosed first for safety monitoring before full enrolment.
• Procedures:
  • Single intramuscular dose (0.5 mL).
  • Safety Monitoring: Solicited adverse events (AEs) recorded via electronic diary for 7 days; unsolicited AEs monitored for 28 days. Vital signs and lab tests (blood/urine) collected at screening, Day 1, and Day 28.
  • Immunogenicity: Measured at Day 1 and Day 28.
    • Anti-Tetanus Toxoid (TT) & Anti-Diphtheria Toxoid (DT): Quantified via ELISA.
    • Functional Antibodies: Diphtheria neutralising antibodies assessed via Vero cell toxin neutralization test (TNT).
• Endpoints:
  • Primary: Incidence of solicited and unsolicited AEs (reactogenicity and tolerability).
  • Secondary: Seroprotection rates at Day 28 (TT ≥1.0 IU/mL; DT ≥0.1 IU/mL and ≥1.0 IU/mL) and Geometric Mean Titre Ratios (GMR).

3. Key Contributions

• First-in-Human Evidence: This is the first clinical trial demonstrating the safety and immunogenicity of a room-temperature-stabilised, aluminium-adjuvanted Td vaccine in humans.
• Technology Validation: Validates the StablevaX platform's ability to reformulate liquid, aluminium-hydroxide adjuvanted vaccines into a lyophilised, freeze-tolerant, and heat-stable format without compromising immunogenicity.
• Scalability: Demonstrates that this technology is applicable beyond Td vaccines, offering a potential solution for stabilizing a broad range of liquid vaccines and biological products.

4. Results

• Safety and Tolerability:
  • No Serious Adverse Events (SAEs): No serious adverse reactions (SARs), suspected unexpected serious adverse reactions (SUSARs), or SAEs occurred.
  • Reactogenicity: 54 participants experienced mild-to-moderate AEs; no severe (Grade 3+) AEs were reported.
  • Comparison: The safety profile of SPVX02 was comparable to both Tetadif and diTeBooster. The most common AE was injection site pain (66.7% overall).
• Immunogenicity (Day 28):
  • Tetanus (TT): 100% of participants in all three groups achieved seroprotective levels (≥1.0 IU/mL).
    • GMR (Day 28 vs. Baseline): SPVX02 (16.6), Tetadif (8.5), diTeBooster (15.5).
  • Diphtheria (DT):
    • Seroprotection (≥0.1 IU/mL): 100% in SPVX02 and Tetadif groups; 95% in diTeBooster.
    • Long-term Seroprotection (≥1.0 IU/mL): 80% (SPVX02), 85% (Tetadif), and 95% (diTeBooster).
    • Neutralising Antibodies: 90% of SPVX02 and Tetadif recipients, and 95% of diTeBooster recipients achieved neutralising titres ≥1.0 IU/mL.
  • Potency Note: diTeBooster showed slightly higher anti-DT GMR (22.8), attributed to its higher diphtheria toxoid content (21 IU/0.5mL) compared to SPVX02 (11.76 IU/0.5mL) and Tetadif (10.74 IU/0.5mL).
• Stability Correlation: Parallel stability studies confirmed SPVX02 maintained potency and attributes after 18 months at 30°C and 6 months at 40°C, and survived three freeze-thaw cycles.

5. Significance

• Global Health Impact: The successful development of SPVX02 addresses a major barrier to immunization in low- and middle-income countries (LMICs). By removing the cold chain requirement, it can significantly reduce vaccine wastage, lower logistical costs, and improve access in remote or conflict-affected areas.
• Environmental Benefit: Eliminating the need for refrigeration and dry ice transport reduces the carbon footprint of vaccine distribution.
• Future Outlook: The study provides the foundational data required to proceed to Phase 2/3 trials for marketing authorization. If successful, the StablevaX technology could be applied to other critical vaccines, transforming global immunization strategies and aligning with the WHO Immunization Agenda 2030.